Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer

Carolyn Krasner, Susana M. Campos, Chantay L. Young, Karan R. Chadda, Hang Lee, Michael J. Birrer, Neil S. Horowitz, Panagiotis A. Konstantinopoulos, Antonella M. D'Ascanio, Ursula A. Matulonis, Richard T. Penson